On 25 June 2024, Evotec announced that its subsidiary, Just – Evotec Biologics, Inc., has been selected by the U.S. Department of Defense to develop an accelerated monoclonal antibody development and manufacturing solution as part of the department’s Manufacturing Optimization Program. The multi-year program award, valued at up to USD$39 million, aims to bolster the U.S. Government’s rapid response capability with biologics medical countermeasures.
Just-Evotec partnered with Sandoz in May of 2023 to develop and manufacture multiple biosimilar medicines (with an option for expansion).